[{"Assets_0_FY_USD":1224400000.0,"CommonStockSharesConverted_0_FY_shares":68400000.0,"CommonStockSharesOutstanding_0_FY_shares":68400000.0,"EarningsPerShareBasic_4_FY_USD":0.32,"EarningsPerShareDiluted_4_FY_USD":0.32,"NetCashProvidedByUsedInOperatingActivitiesConverted_4_FY_USD":106200000.0,"NetIncomeLossConverted_4_FY_USD":21600000.0,"RevenuesConverted_4_FY_USD":771400000.0,"StockholdersEquity_0_FY_USD":778200000.0,"StockholdersEquityConverted_0_FY_USD":777800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":68800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":68300000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-K","period":"20170630","fy":"2017.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170809"}]